QUANTA Lite®

DGP Tests



Accuracy

Detects celiac disease patients missed by other assays[1]



Data adapted from Dahle et al.[5]

QUANTA Lite DGP tests provide a more accurate picture for celiac disease diagnosis.

- Deamidated Gliadin Peptide (DGP) offers an important complement to tTG, increasing sensitivity for celiac disease[2,3]
- Using DGP and tTG in combination helps to stratify patients for biopsy or gluten-free diet[2]
- The QUANTA Lite DGP test is effective in detecting patients with IgA deficiencies, pediatric patients, and hemolyzed samples[1,2,4]

Werfen Group | INOVA Diagnostics, Inc.

QUANTA Lite®

DGP Tests

Clinical study results[3]

Sensitive

- DGP IgA, DGP IgG, and DGP Screen offered sensitivities of 98.4%, 95.2%, and 96.8%, respectively
- tTG/DGP Screen was found to detect 100% of celiac patients

Specific

- DGP IgA, DGP IgG, and DGP Screen achieved a specificity up to 92.7%, 100%, and 99.0%, respectively
- tTG/DGP Screen attained a specificity of 92.8%

Performance of QUANTA Lite celiac disease tests in a high-risk population (n=679)

Test	Sensitivity (95% CI)	Specificity (95% CI)
tTG IgA	95.2% (86.7-99.0%)	97.9% (92.8-99.7%)
DGP IgA	98.4% (91.4-99.7%)	92.7% (85.5-97.1%)
DGP IgG	95.2% (86.7-99.0%)	100.0% (96.2-100.0%)
DGP Screen (IgA/IgG)	96.8% (89.0-99.5%)	99.0% (94.4-99.8%)
tTG/DGP Screen	100.0% (94.3-100.0%)	92.8% (85.8-97.1%)

Data adapted from Sugai et al.[3]

Accuracy starts with high-quality reagents

- QUANTA Lite DGP, in combination with tTG, results in the best initial test for celiac disease diagnosis
- The use of DGP, in combination with tTG, increases diagnostic accuracy and may obviate the need for biopsy in more than 92% of individuals[3]
- The QUANTA Lite DGP tests pioneered the use of deamidated gliadin peptides with clinical utility demonstrated in peer reviewed journals worldwide[1-5]
- INOVA offers high-quality products, and unmatched service and product support expertise

Available in a variety of configurations

QUANTA Lite DGP tests are ideally used in conjunction with other QUANTA Lite celiac tests.

Product Ordering Information	IgA	IgG	Screen (IgA/IgG)
QUANTA Lite Gliadin II (DGP)	704525	704520	704545
QUANTA Lite h-tTG/DGP Screen			704575
QUANTA Lite h-tTG (Human Tissue Transglutaminase)	708760	708755	704570
QUANTA Lite R h-tTG (Recombinant Human Tissue Transglutaminase)	704605	704610	
QUANTA Lite h-tTG (Guinea Pig Tissue Transglutaminase)	708730		
QUANTA Lite Gliadin	708655	708650	
QUANTA Lite F-Actin	704500		

For more information, visit www.inovadx.com.

References

1. Korponay-Szabo. Coeliac antibody testing with deamidated gliadin peptides in difficult patient samples. *Gut.* 2007;56(Suppl III):A109.
2. Volta U, Granito A, Parisi C, et al. Deamidated gliadin peptide antibodies as a routine test for celiac disease: a prospective analysis. *J Clin Gastroenterol.* 2010;44(3):186-190.
3. Sugai E, Moreno ML, Hwang HJ, et al. Celiac disease serology in patients with different pretest probabilities: is biopsy avoidable? *World J Gastroenterol.* 2010;16(25):3144-3152.
4. Arguelles-Grande C, Norman GL, Bhagat G, Green PH. Hemolysis interferes with the detection of anti-tissue transglutaminase antibodies in celiac disease. *Clin Chem.* 2010;56(6):1034-1036.
5. Dahle, C., A. Hagman, et al. (2010). Antibodies against deamidated gliadin peptides identify adult coeliac disease patients negative for antibodies against endomysium and tissue transglutaminase. *Aliment Pharmacol Ther* 32(2): 254-260.

Werfen Group | INOVA Diagnostics, Inc.

Redefining Autoimmunity.

San Diego, CA 92131 USA
PH: +1-858-586-9900 US Toll Free: 1-800-545-9495 FAX: +1-858-586-9911

690168 November 2010 Rev. 1